DEFA14A: Premier to Go Private in $28.25/Share Patient Square Deal

Premier, Inc. announced an agreement to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash, transitioning to a private company.

Summary

• Premier, Inc. has agreed to be acquired by an affiliate of Patient Square Capital for $28.25 per share in cash.
• The transaction will result in Premier becoming a private company, with its stock no longer listed on NASDAQ or any other public exchange.
• Premier's Board of Directors unanimously determined the transaction is in the best interests of Premier and its stockholders, delivering immediate and certain value.
• Patient Square Capital is a dedicated healthcare investment firm with deep industry expertise and significant capital.
• As a private company, Premier expects to benefit from enhanced financial flexibility, access to additional capital and resources to accelerate product advancement, tech-enablement, and innovation.
• The transaction is expected to be completed by the first quarter of calendar year 2026.
• Completion is subject to approval by Premier stockholders, regulatory approvals, and other customary closing conditions.

Sentiment

Score: 8

Explanation: The acquisition provides immediate and certain cash value to shareholders, representing a positive outcome. For the company, the transition to private ownership with Patient Square Capital's financial backing and industry expertise is presented as a strategic move to enhance growth, innovation, and market responsiveness.

Positives

• Stockholders will receive immediate and certain value of $28.25 per share in cash.
• Premier will gain enhanced financial flexibility and access to additional capital and resources as a private company.
• The partnership with Patient Square Capital is expected to accelerate the advancement and tech-enablement of Premier's product portfolio.
• The acquisition will allow Premier to capitalize on emerging opportunities and continue pushing innovation in healthcare.
• Patient Square Capital brings deep industry expertise and a strong track record of helping companies reach their full potential.

Negatives

• Premier's stock will no longer be listed or trade on NASDAQ or any other public exchange once the transaction closes, removing public investment opportunities.
• The transition to a private company may alter the company's operational transparency and reporting requirements.

Risks

• Inability to consummate the proposed transaction within the anticipated time period, or at all, due to failure to obtain required regulatory approvals, stockholder approval, or complete financing arrangements.
• Adverse effects on the market price of Premier Class A Common Stock due to announcements related to the proposed transaction.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with customers, vendors, and others.
• Occurrence of any event, change, or other circumstances that could give rise to the termination of the merger agreement.
• Risks related to disruption of current plans and operations or diversion of management's attention from ongoing business operations due to the proposed transaction.
• Significant transaction costs associated with the acquisition.
• Risk of litigation and/or regulatory actions related to the proposed transaction or unfavorable results from currently pending or future litigation and proceedings.

Future Outlook

Premier will transition to a private company, gaining enhanced financial flexibility and access to additional capital and resources from Patient Square Capital. This is expected to accelerate the advancement and tech-enablement of its product portfolio, enable capitalization on emerging opportunities, and foster continued innovation to meet evolving market needs.

Management Comments

• "This announcement is the result of our intentional strategy to best position Premier for the long term and benefit all stakeholders."
• "Premier's Board of Directors carefully considered a wide range of strategic alternatives in recent years and unanimously determined that this transaction with Patient Square is in the best interests of Premier and its stockholders."
• "Patient Square has deep industry expertise, significant capital and a strong track record of successfully helping companies like Premier reach their full potential."
• "As a private company with Patient Square's financial support, Premier will benefit from access to additional capital and resources."
• "Patient Square understands our business model and strategy, believes in our team and our mission to improve the health of communities, and shares our commitments to people, integrity, innovation and high performance."
• "We look forward to continuing to elevate patient care and make healthcare better through this partnership."
• "Until the transaction closes, Premier will continue to operate as a public company, and it is business as usual."

Industry Context

This acquisition reflects a broader trend of private equity investment in the healthcare sector, particularly in companies offering supply chain expertise, technology, and advisory services. Patient Square Capital's focus on improving health through products, services, and technologies aligns with the strategic value proposition of Premier, suggesting a move towards consolidating and enhancing healthcare infrastructure through private capital.

Corporate Governance

Stakeholder Impact

• Shareholders: Will receive $28.25 per share in cash, providing immediate and certain value for their investment.
• Employees: Expected to continue with 'business as usual' until closing, with the company emphasizing Patient Square's belief in the team and mission. Potential for enhanced resources and innovation could impact future roles and opportunities.
• Members/Customers/Partners: The transaction is intended to benefit these stakeholders by accelerating product advancement, tech-enablement, and innovation to meet evolving market needs.
• Regulatory Authorities: The transaction is subject to regulatory approvals, indicating potential scrutiny of market impact and competition.

Next Steps

• Premier stockholders' approval of the transaction.
• Obtaining necessary regulatory approvals.
• Satisfaction of other customary closing conditions.
• Premier will file relevant materials with the SEC, including a proxy statement on Schedule 14A.
• An all-employee town hall will be hosted today at 11:30 AM ET to discuss the news in greater detail.

Key Dates

Recommendation

The acquisition by Patient Square Capital at a fixed cash price of $28.25 per share provides a clear exit value for existing shareholders. A 'hold' recommendation is appropriate for shareholders to realize this value upon the expected closing of the transaction in Q1 2026, assuming the current market price is at or below the offer price and the deal is likely to close.

Keywords

Healthcare, Acquisition, Take-private, Patient Square Capital, Premier Inc, Supply Chain, Advisory, Technology, Merger